Corporate Profile

CalciMedica is a clinical-stage biopharmaceutical company advancing calcium release-activated calcium (CRAC) channel inhibitors to address serious inflammatory, immunologic and cardiopulmonary diseases.

Our pipeline includes two distinct investigational compounds: zegocractin, administered intravenously as Auxora™, and CM5480, an oral candidate intended for chronic dosing. Auxora has been evaluated in more than 350 patients. Its development plans include a Phase 1b proof-of-concept trial in pulmonary arterial hypertension and a Phase 2b trial in acute pancreatitis. Initiation of the acute pancreatitis trial is subject to additional financing. CM5480 is being developed for pulmonary hypertension, with an Investigational New Drug (IND) application submission anticipated in mid-2027.

Learn More

Stock Information

Minimum 15 minutes delayed. Source: LSEG

Featured Events

More events are coming soon.
View all Events

Corporate Presentation

View Presentation

Press Releases

10 Nov 26

CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Auxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both anticipated in mid-2027 Cash, cash equivalents and short-term investments of $13.8 million as of September 30, 2026; cash expected to fund current operating plan into the second half of 2027 LA
03 Nov 26

CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and
08 Sep 26

CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and
27 Aug 26

CalciMedica Announces One-for-Five Reverse Stock Split

CalciMedica’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 31, 2026 LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated
View all Releases
Explore More
Our Science
Our Pipeline
Our Publications
About Us